Curis | CRIS - Operating Profit


Curis reported $-12.51M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Curis USD -12.51M 40K Jun/2024
Eli Lilly USD 8.99B 599.9M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Takeda JPY 168.82B 479.89B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -18.28M 9.78M Jun/2024
Xoma USD -15.64M 5.56M Sep/2024